0001209191-22-005202.txt : 20220127
0001209191-22-005202.hdr.sgml : 20220127
20220127162740
ACCESSION NUMBER: 0001209191-22-005202
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220125
FILED AS OF DATE: 20220127
DATE AS OF CHANGE: 20220127
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: STACK DAVID M
CENTRAL INDEX KEY: 0001204788
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 22563522
MAIL ADDRESS:
STREET 1: THE MEDICINES CO
STREET 2: 8 CAMPUS DRIVE
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira BioSciences, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 510619477
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5401 WEST KENNEDY BOULEVARD
STREET 2: SUITE 890
CITY: TAMPA
STATE: FL
ZIP: 33609
BUSINESS PHONE: 813-553-6680
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20101029
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-25
0
0001396814
Pacira BioSciences, Inc.
PCRX
0001204788
STACK DAVID M
C/O PACIRA BIOSCIENCES, INC.
5401 WEST KENNEDY BOULEVARD, SUITE 890
TAMPA
FL
33609
1
1
0
0
CEO and Chairman
Common Stock
2022-01-25
4
M
0
13670
10.81
A
123044
D
Common Stock
97273
I
By Three Colleens Investment, LLC
Common Stock
18596
I
By Stack Schroon Mohawk FLP
Common Stock
315
I
LCK Investment LLC
Stock Option (Right to Buy)
10.81
2022-01-25
4
M
0
13670
0.00
D
2022-06-05
Common Stock
13670
45000
D
Mr. Stack and his wife are the owners of each of Three Colleens Investment, LLC and LCK Investment LLC. Mr. Stack is the general partner of Stack Schroon Mohawk FLP.
The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months.
/s/ Kristen Williams, Attorney-in-Fact
2022-01-27